|
1
|
Nandakumar P, Mansouri A and Das S: The
role of ATRX in glioma biology. Front Oncol. 7:2362017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yuan Y, Qi C, Maling G, Xiang W, Yanhui L,
Ruofei L, Yunhe M, Jiewen L and Qing M: TERT mutation in glioma:
Frequency, prognosis and risk. J Clin Neurosci. 26:57–62. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heidenreich B, Rachakonda PS, Hemminki K
and Kumar R: TERT promoter mutations in cancer development. Curr
Opin Genet Dev. 24:30–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walsh KM, Codd V, Smirnov IV, Rice T,
Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS,
et al: Variants near TERT and TERC influencing telomere length are
associated with high-grade glioma risk. Nat Genet. 46:731–735.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arita H, Narita Y, Fukushima S, Tateishi
K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP,
Kawahara N, et al: Upregulating mutations in the TERT promoter
commonly occur in adult malignant gliomas and are strongly
associated with total 1p19q loss. Acta Neuropathol. 126:267–276.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eckel-Passow JE, Lachance DH, Molinaro AM,
Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML,
Smirnov IV, et al: Glioma groups based on 1p/19q, IDH, and TERT
promoter mutations in tumors. N Engl J Med. 372:2499–2508. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ceccarelli M, Barthel FP, Malta TM,
Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh
A, Pagnotta SM, et al: Molecular profiling reveals biologically
discrete subsets and pathways of progression in diffuse glioma.
Cell. 164:550–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heaphy CM, Subhawong AP, Hong SM, Goggins
MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL,
Westra WH, et al: Prevalence of the alternative lengthening of
telomeres telomere maintenance mechanism in human cancer subtypes.
Am J Pathol. 179:1608–1615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hewer E, Vajtai I, Dettmer MS, Berezowska
S and Vassella E: Combined ATRX/IDH1 immunohistochemistry predicts
genotype of oligoastrocytomas. Histopathology. 68:272–278. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiao Y, Killela PJ, Reitman ZJ, Rasheed
AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo
SM, Nagahashi Marie SK, et al: Frequent ATRX, CIC, FUBP1 and IDH1
mutations refine the classification of malignant gliomas.
Oncotarget. 3:709–722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kannan K, Inagaki A, Silber J, Gorovets D,
Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA and Huse JT:
Whole-exome sequencing identifies ATRX mutation as a key molecular
determinant in lower-grade glioma. Oncotarget. 3:1194–1203. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JC, Jeng YM, Liau JY, Tsai JH, Hsu HH
and Yang CY: Alternative lengthening of telomeres and loss of ATRX
are frequent events in pleomorphic and dedifferentiated
liposarcomas. Mod Pathol. 28:1064–1073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu XY, Gerges N, Korshunov A, Sabha N,
Khuong-Quang DA, Fontebasso AM, Fleming A, Hadjadj D,
Schwartzentruber J, Majewski J, et al: Frequent ATRX mutations and
loss of expression in adult diffuse astrocytic tumors carrying
IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 124:615–625. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wiestler B, Capper D, Holland-Letz T,
Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M and
Wick W: ATRX loss refines the classification of anaplastic gliomas
and identifies a subgroup of IDH mutant astrocytic tumors with
better prognosis. Acta Neuropathol. 126:443–451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karsy M, Guan J, Cohen AL, Jensen RL and
Colman H: New molecular considerations for glioma: IDH, ATRX, BRAF,
TERT, H3 K27M. Curr Neurol Neurosci Rep. 17:192017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Armanios M: Telomeres and age-related
disease: How telomere biology informs clinical paradigms. J Clin
Invest. 123:996–1002. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rodriguez FJ, Scheithauer BW, Burger PC,
Jenkins S and Giannini C: Anaplasia in pilocytic astrocytoma
predicts aggressive behavior. Am J Surg Pathol. 34:147–160. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
López-Otín C, Blasco MA, Partridge L,
Serrano M and Kroemer G: The hallmarks of aging. Cell.
153:1194–1217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Podlevsky JD and Chen JJ: It all comes
together at the ends: Telomerase structure, function, and
biogenesis. Mutat Res. 730:3–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanaya T, Kyo S, Hamada K, Takakura M,
Kitagawa Y, Harada H and Inoue M: Adenoviral expression of p53
represses telomerase activity through down-regulation of human
telomerase reverse transcriptase transcription. Clin Cancer Res.
6:1239–1247. 2000.PubMed/NCBI
|
|
24
|
Farooqi AS, Dagg RA, Choi LM, Shay JW,
Reynolds CP and Lau LM: Alternative lengthening of telomeres in
neuroblastoma cell lines is associated with a lack of MYCN genomic
amplification and with p53 pathway aberrations. J Neurooncol.
119:17–26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Venneti S and Huse JT: The evolving
molecular genetics of low-grade glioma. Adv Anat Pathol. 22:94–101.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gibbons RJ, Wada T, Fisher CA, Malik N,
Mitson MJ, Steensma DP, Fryer A, Goudie DR, Krantz ID and
Traeger-Synodinos J: Mutations in the chromatin-associated protein
ATRX. Hum Mutat. 29:796–802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gibbons RJ, Pellagatti A, Garrick D, Wood
WG, Malik N, Ayyub H, Langford C, Boultwood J, Wainscoat JS and
Higgs DR: Identification of acquired somatic mutations in the gene
encoding chromatin-remodeling factor ATRX in the alpha-thalassemia
myelodysplasia syndrome (ATMDS). Nat Genet. 34:446–449. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heaphy CM, de Wilde RF, Jiao Y, Klein AP,
Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG and Hebbar
S: Altered telomeres in tumors with ATRX and DAXX mutations.
Science. 333:4252011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pickett HA and Reddel RR: Molecular
mechanisms of activity and derepression of alternative lengthening
of telomeres. Nat Struct Mol Biol. 22:875–880. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schwartzentruber J, Korshunov A, Liu XY,
Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA,
Tönjes M, et al: Driver mutations in histone H3.3 and chromatin
remodelling genes in paediatric glioblastoma. Nature. 482:226–231.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Elsässer SJ, Allis CD and Lewis PW:
Cancer. New epigenetic drivers of cancers. Science. 331:1145–1146.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pekmezci M, Rice T, Molinaro AM, Walsh KM,
Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G,
et al: Adult infiltrating gliomas with WHO 2016 integrated
diagnosis: Additional prognostic roles of ATRX and TERT. Acta
Neuropathol. 133:1001–1016. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
van den Bent MJ, Brandes AA, Taphoorn MJ,
Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen
CC, Grisold W, et al: Adjuvant procarbazine, lomustine, and
vincristine chemotherapy in newly diagnosed anaplastic
oligodendroglioma: Long-term follow-up of EORTC brain tumor group
study 26951. J Clin Oncol. 31:344–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bassett AR, Cooper SE, Ragab A and Travers
AA: The chromatin remodelling factor dATRX is involved in
heterochromatin formation. PLoS One. 3:e20992008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Turcan S, Rohle D, Goenka A, Walsh LA,
Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al: IDH1
mutation is sufficient to establish the glioma hypermethylator
phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cai J, Zhu P, Zhang C, Li Q, Wang Z, Li G,
Wang G, Yang P, Li J, Han B, et al: Detection of ATRX and
IDH1-R132H immunohistochemistry in the progression of 211 paired
gliomas. Oncotarget. 7:16384–16395. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leeper HE, Caron AA, Decker PA, Jenkins
RB, Lachance DH and Giannini C: IDH mutation, 1p19q codeletion and
ATRX loss in WHO grade II gliomas. Oncotarget. 6:30295–30305. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Castelo-Branco P, Choufani S, Mack S,
Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D,
Merino D, et al: Methylation of the TERT promoter and risk
stratification of childhood brain tumours: An integrative genomic
and molecular study. Lancet Oncol. 14:534–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koelsche C, Sahm F, Capper D, Reuss D,
Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, et
al: Distribution of TERT promoter mutations in pediatric and adult
tumors of the nervous system. Acta Neuropathol. 126:907–915. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Taphoorn MJ: Neurocognitive sequelae in
the treatment of low-grade gliomas. Semin Oncol. 30:45–48. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Klöppel G, Perren A and Heitz PU: The
gastroenteropancreatic neuroendocrine cell system and its tumors:
The WHO classification. Ann N Y Acad Sci. 1014:13–27. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ishihara M, Mukai H, Nagai S, Onozawa M,
Nihei K, Shimada T and Wada N: Retrospective analysis of risk
factors for central nervous system metastases in operable breast
cancer: Effects of biologic subtype and Ki67 overexpression on
survival. Oncology. 84:135–140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nakano T, Ohno T, Ishikawa H, Suzuki Y and
Takahashi T: Current advancement in radiation therapy for uterine
cervical cancer. J Radiat Res. 51:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hu HY, Liu H, Zhang JW, Hu K and Lin Y:
Clinical significance of Smac and Ki-67 expression in pancreatic
cancer. Hepatogastroenterology. 59:2640–2643. 2012.PubMed/NCBI
|
|
47
|
Liu YZ, Jiang YY, Hao JJ, Lu SS, Zhang TT,
Shang L, Cao J, Song X, Wang BS, Cai Y, et al: Prognostic
significance of MCM7 expression in the bronchial brushings of
patients with non-small cell lung cancer (NSCLC). Lung Cancer.
77:176–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Golmohammadi R and Pejhan A: The
prognostic value of the P53 protein and the Ki67 marker in breast
cancer patients. J Pak Med Assoc. 62:871–875. 2012.PubMed/NCBI
|
|
49
|
Boonyaphiphat P, Pruegsanusak K and
Thongsuksai P: The prognostic value of p53, Bcl-2 and Bax
expression in laryngeal cancer. J Med Assoc Thai. 95:1317–1320.
2012.PubMed/NCBI
|
|
50
|
Ben-Izhak O, Bar-Chana M, Sussman L,
Dobiner V, Sandbank J, Cagnano M, Cohen H and Sabo E: Ki67 antigen
and PCNA proliferation markers predict survival in anorectal
malignant melanoma. Histopathology. 41:519–525. 2002. View Article : Google Scholar : PubMed/NCBI
|
